Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03217721
Other study ID # 29BRC17.0092
Secondary ID
Status Completed
Phase N/A
First received July 5, 2017
Last updated September 29, 2017
Start date June 19, 2017
Est. completion date September 19, 2017

Study information

Verified date July 2017
Source University Hospital, Brest
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Neutropenia, defined by an absolute count of polymorphonuclear neutrophils less than <1500/mm3, exposes patients to infectious complications that can lead to sepsis or septic shock. The mortality risk is higher risk. The recommendations published in 2016 were formulated to homogenize the clinical practices to improve the survival.


Description:

We evaluate the adequacy antibiotics prescriptions in febrile neutropenia with suspected infection and evaluate factors influencing adequacy therapy and mortality consequence.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 19, 2017
Est. primary completion date September 19, 2017
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Sepsis or septic shock at admission or during the stay

Exclusion Criteria:

- Minor

- Pregnancy

- Opposition

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France CHRU de Brest Brest

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

References & Publications (1)

Schnell D, Azoulay E, Benoit D, Clouzeau B, Demaret P, Ducassou S, Frange P, Lafaurie M, Legrand M, Meert AP, Mokart D, Naudin J, Pene F, Rabbat A, Raffoux E, Ribaud P, Richard JC, Vincent F, Zahar JR, Darmon M. Management of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French Society of Anesthesia and Intensive Care (SFAR), the French Society of Hematology (SFH), the French Society for Hospital Hygiene (SF2H), and the French Infectious Diseases Society (SPILF). Ann Intensive Care. 2016 Dec;6(1):90. doi: 10.1186/s13613-016-0189-6. Epub 2016 Sep 15. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of adequate antibiotic prescription Proportion of adequate antibiotic prescription Through study completion, an average of 1 month
Secondary Mortality of all causes Mortality of all causes ICU, hospital and 28-day mortality
See also
  Status Clinical Trial Phase
Recruiting NCT04637464 - Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer N/A
Completed NCT03511820 - A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever
Not yet recruiting NCT04260230 - Remote Monitoring of Patients at Risk of Sepsis N/A
Completed NCT04187755 - Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever Phase 4
Completed NCT04669418 - Host RNA Signature in Children With Cancer and Infection
Recruiting NCT04938206 - DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule N/A
Terminated NCT03003273 - Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study Phase 3
Recruiting NCT05926063 - Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia Phase 4
Not yet recruiting NCT05852249 - Investigation of the Usability of Neutrocheck Amongst Healthy Volunteers and Healthcare Professionals.
Withdrawn NCT05061654 - CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients Phase 4
Recruiting NCT02474550 - Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma N/A